The search for treatments to reduce chemotherapy-induced peripheral neuropathy

Deirdre R. Pachman, Charles Lawrence Loprinzi, Axel F Grothey, Lauren E. Ta

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Oxaliplatin, a commonly used chemotherapeutic agent, is associated with both acute and chronic neurotoxicity. Chronic sensory neuropathy can be dose limiting and may have detrimental effects on patients' quality of life. Preclinical studies provide an understanding of the pathophysiology of chemotherapy- induced peripheral neuropathy (CIPN) and may be important for developing effective preventative interventions. In this issue of the JCI, Coriat and colleagues used an animal model and a human pilot trial to evaluate the use of mangafodipir to reduce CIPN. Although many pilot clinical studies have reported promising data, larger clinical trials have repeatedly been unable to confirm these preliminary results. Thus, no agents are currently clinically recommended for the prevention of CIPN.

Original languageEnglish (US)
Pages (from-to)72-74
Number of pages3
JournalJournal of Clinical Investigation
Volume124
Issue number1
DOIs
StatePublished - Jan 2 2014

Fingerprint

Peripheral Nervous System Diseases
oxaliplatin
Drug Therapy
Therapeutics
Animal Models
Quality of Life
Clinical Trials

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The search for treatments to reduce chemotherapy-induced peripheral neuropathy. / Pachman, Deirdre R.; Loprinzi, Charles Lawrence; Grothey, Axel F; Ta, Lauren E.

In: Journal of Clinical Investigation, Vol. 124, No. 1, 02.01.2014, p. 72-74.

Research output: Contribution to journalArticle

Pachman, Deirdre R. ; Loprinzi, Charles Lawrence ; Grothey, Axel F ; Ta, Lauren E. / The search for treatments to reduce chemotherapy-induced peripheral neuropathy. In: Journal of Clinical Investigation. 2014 ; Vol. 124, No. 1. pp. 72-74.
@article{968ab8940ff94a2a8adb4373b4d7da07,
title = "The search for treatments to reduce chemotherapy-induced peripheral neuropathy",
abstract = "Oxaliplatin, a commonly used chemotherapeutic agent, is associated with both acute and chronic neurotoxicity. Chronic sensory neuropathy can be dose limiting and may have detrimental effects on patients' quality of life. Preclinical studies provide an understanding of the pathophysiology of chemotherapy- induced peripheral neuropathy (CIPN) and may be important for developing effective preventative interventions. In this issue of the JCI, Coriat and colleagues used an animal model and a human pilot trial to evaluate the use of mangafodipir to reduce CIPN. Although many pilot clinical studies have reported promising data, larger clinical trials have repeatedly been unable to confirm these preliminary results. Thus, no agents are currently clinically recommended for the prevention of CIPN.",
author = "Pachman, {Deirdre R.} and Loprinzi, {Charles Lawrence} and Grothey, {Axel F} and Ta, {Lauren E.}",
year = "2014",
month = "1",
day = "2",
doi = "10.1172/JCI73908",
language = "English (US)",
volume = "124",
pages = "72--74",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "1",

}

TY - JOUR

T1 - The search for treatments to reduce chemotherapy-induced peripheral neuropathy

AU - Pachman, Deirdre R.

AU - Loprinzi, Charles Lawrence

AU - Grothey, Axel F

AU - Ta, Lauren E.

PY - 2014/1/2

Y1 - 2014/1/2

N2 - Oxaliplatin, a commonly used chemotherapeutic agent, is associated with both acute and chronic neurotoxicity. Chronic sensory neuropathy can be dose limiting and may have detrimental effects on patients' quality of life. Preclinical studies provide an understanding of the pathophysiology of chemotherapy- induced peripheral neuropathy (CIPN) and may be important for developing effective preventative interventions. In this issue of the JCI, Coriat and colleagues used an animal model and a human pilot trial to evaluate the use of mangafodipir to reduce CIPN. Although many pilot clinical studies have reported promising data, larger clinical trials have repeatedly been unable to confirm these preliminary results. Thus, no agents are currently clinically recommended for the prevention of CIPN.

AB - Oxaliplatin, a commonly used chemotherapeutic agent, is associated with both acute and chronic neurotoxicity. Chronic sensory neuropathy can be dose limiting and may have detrimental effects on patients' quality of life. Preclinical studies provide an understanding of the pathophysiology of chemotherapy- induced peripheral neuropathy (CIPN) and may be important for developing effective preventative interventions. In this issue of the JCI, Coriat and colleagues used an animal model and a human pilot trial to evaluate the use of mangafodipir to reduce CIPN. Although many pilot clinical studies have reported promising data, larger clinical trials have repeatedly been unable to confirm these preliminary results. Thus, no agents are currently clinically recommended for the prevention of CIPN.

UR - http://www.scopus.com/inward/record.url?scp=84892932028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84892932028&partnerID=8YFLogxK

U2 - 10.1172/JCI73908

DO - 10.1172/JCI73908

M3 - Article

AN - SCOPUS:84892932028

VL - 124

SP - 72

EP - 74

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 1

ER -